Insulet (NASDAQ:PODD) Price Target Raised to $355.00 at UBS Group

Insulet (NASDAQ:PODD) had its price objective raised by UBS Group from $320.00 to $355.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a neutral rating on the medical instruments supplier’s stock.

Several other research firms have also issued reports on PODD. Oppenheimer lifted their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. Leerink Partners raised their price objective on shares of Insulet from $355.00 to $385.00 and gave the stock an “outperform” rating in a report on Friday. Stifel Nicolaus assumed coverage on shares of Insulet in a research report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $370.00 price objective on shares of Insulet in a research report on Thursday. Finally, Wolfe Research boosted their price target on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $370.76.

Insulet Trading Down 1.1%

Shares of PODD traded down $3.58 during midday trading on Friday, hitting $319.82. The stock had a trading volume of 677,166 shares, compared to its average volume of 721,278. Insulet has a fifty-two week low of $230.05 and a fifty-two week high of $353.50. The business has a 50-day simple moving average of $325.06 and a two-hundred day simple moving average of $309.40. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm has a market cap of $22.51 billion, a P/E ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s revenue for the quarter was up 29.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts forecast that Insulet will post 3.92 EPS for the current year.

Insider Buying and Selling

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Insulet by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after buying an additional 87,845 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Insulet by 3.1% in the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock valued at $603,211,000 after buying an additional 58,309 shares during the period. American Century Companies Inc. raised its stake in shares of Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after acquiring an additional 297,734 shares during the last quarter. Groupama Asset Managment lifted its holdings in Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after buying an additional 3,759 shares during the period. Finally, Norges Bank bought a new position in Insulet during the second quarter worth $324,689,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.